EyeGate Pharmaceuticals (EYEG) 10-Q 12 Aug 15 2015 Q2 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	6 Months Ended
	Jun. 30, 2015	Aug. 12, 2015
Document Information [Line Items]
Entity Registrant Name	EYEGATE PHARMACEUTICALS INC
Entity Central Index Key	1,372,514
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Trading Symbol	EYEG
Entity Common Stock, Shares Outstanding		7,653,563
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2015
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	Q2

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($)	Jun. 30, 2015	Dec. 31, 2014
Current assets:
Cash and cash equivalents	$ 1,273,965	$ 167,001
Prepaid expenses and other current assets	133,649	26,443
Current portion of refundable tax credit receivable	22,501	25,336
Total current assets	1,430,115	218,780
Property and equipment, net	573	1,257
Restricted cash	20,000	0
Deferred offering costs	68,517	1,148,994
Other assets	37,112	37,439
Total assets	1,556,317	1,406,470
Current liabilities:
Grants payable	0	36,401
Accounts payable	337,610	565,947
Accrued expenses	304,998	913,063
Convertible notes due to stockholders, net (aggregate principal outstanding of $3,376,573 at December 31, 2014)	0	3,205,504
Warrant liability	0	303,102
Total current liabilities	$ 642,608	$ 5,024,017
Commitments and contingencies (Note 12)
Convertible preferred stock and non-controlling interests: (classified as temporary equity)
Non-controlling interests	$ 0	$ 6,780,588
Total convertible preferred stock and non-controlling interests	0	43,189,254
Stockholders’ equity (deficit):
Preferred stock, $0.01 par value; 10,000,000 shares authorized, 0 issued and outstanding at June 30, 2015	0	0
Common stock, $0.01 par value: 100,000,000 shares authorized; 6,477,093 shares issued at June 30, 2015 and 201,787 shares issued at December 31, 2014	64,771	2,018
Additional paid-in capital	62,012,640	10,055,613
Accumulated deficit	(61,209,768)	(56,862,152)
Shareholder notes receivable	(58,824)	(58,824)
Accumulated other comprehensive income	104,890	56,544
Total stockholders’ equity (deficit)	913,709	(46,806,801)
Total liabilities, convertible preferred stock, non-controlling interests and stockholders’ equity (deficit)	1,556,317	1,406,470
Series A Convertible Preferred Stock [Member]
Convertible preferred stock and non-controlling interests: (classified as temporary equity)
Convertible preferred stock	0	254,525
Series B Convertible Preferred Stock [Member]
Convertible preferred stock and non-controlling interests: (classified as temporary equity)
Convertible preferred stock	0	6,926,180
Series C Convertible Preferred Stock [Member]
Convertible preferred stock and non-controlling interests: (classified as temporary equity)
Convertible preferred stock	0	5,745,127
Series D Convertible Preferred Stock [Member]
Convertible preferred stock and non-controlling interests: (classified as temporary equity)
Convertible preferred stock	$ 0	$ 23,482,834

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)	Jun. 30, 2015	Dec. 31, 2014
Long-term Debt, Gross		$ 3,376,573
Common Stock, Par or Stated Value Per Share	$ 0.01	$ 0.01
Common Stock, Shares Authorized	100,000,000	100,000,000
Common Stock, Shares, Issued	6,477,093	201,787
Preferred Stock, Par or Stated Value Per Share	$ 0.01	$ 0.01
Preferred Stock, Shares Authorized	10,000,000	10,000,000
Preferred Stock, Shares Issued	0	0
Preferred Stock, Shares Outstanding	0	0
Series A Convertible Preferred Stock [Member]
Temporary Equity, Par or Stated Value Per Share	$ 0.01	$ 0.01
Temporary Equity, Shares Authorized	2,483,692	2,483,692
Temporary Equity, Shares Issued	0	2,483,692
Temporary Equity, Shares Outstanding	0	2,483,692
Temporary Equity, Liquidation Preference		$ 5,960,863
Preferred Stock, Shares Authorized	2,483,692
Preferred Stock, Shares Outstanding		2,483,692
Series B Convertible Preferred Stock [Member]
Temporary Equity, Par or Stated Value Per Share	$ 0.01	$ 0.01
Temporary Equity, Shares Authorized	13,794,259	13,794,259
Temporary Equity, Shares Issued	0	8,073,508
Temporary Equity, Shares Outstanding	0	8,073,508
Temporary Equity, Liquidation Preference		$ 7,023,952
Preferred Stock, Shares Authorized	13,819,649
Preferred Stock, Shares Outstanding		8,073,508
Series C Convertible Preferred Stock [Member]
Temporary Equity, Par or Stated Value Per Share	$ 0.01	$ 0.01
Temporary Equity, Shares Authorized	5,161,236	5,161,236
Temporary Equity, Shares Issued	0	3,351,156
Temporary Equity, Shares Outstanding	0	3,351,156
Temporary Equity, Liquidation Preference		$ 5,857,140
Preferred Stock, Shares Authorized	5,161,241
Preferred Stock, Shares Outstanding		3,351,156
Series D Convertible Preferred Stock [Member]
Temporary Equity, Par or Stated Value Per Share	$ 0.01	$ 0.01
Temporary Equity, Shares Authorized	24,023,485	24,023,485
Temporary Equity, Shares Issued	0	19,557,392
Temporary Equity, Shares Outstanding	0	19,557,392
Temporary Equity, Liquidation Preference		$ 23,762,876
Preferred Stock, Shares Authorized	29,020,554
Preferred Stock, Shares Outstanding		19,557,392

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Operating expenses:
Research and development	$ 604,108	$ 92,435	$ 925,547	$ 310,303
General and administrative	939,487	510,244	1,722,333	1,166,460
Total operating expenses	1,543,595	602,679	2,647,880	1,476,763
Other income (expense), net:
Research and development tax credit	0	22,575	0	25,515
Interest income	2,242	324	2,406	631
Interest expense	0	(62,154)	(1,920,146)	(94,209)
Change in warrant liability	0	(5,000)	223,172	(5,000)
Other income (expense), net	0	0	9	0
Total other income (expense), net	2,242	(44,255)	(1,694,559)	(73,063)
Net Loss	(1,541,353)	(646,934)	(4,342,439)	(1,549,826)
Deemed dividend on preferred stock	0	0	(8,222,008)	0
Net income attributable to non-controlling interests	0	(58,314)	(5,177)	(117,262)
Net loss attributable to Eyegate Pharmaceuticals, Inc. common stockholders	$ (1,541,353)	$ (705,248)	$ (12,569,624)	$ (1,667,088)
Net loss per common share - basic and diluted	$ (0.24)	$ (3.82)	$ (2.57)	$ (9.04)
Weighted average shares outstanding - basic and diluted	6,363,027	184,474	4,898,405	184,474
Net loss	$ (1,541,353)	$ (646,934)	$ (4,342,439)	$ (1,549,826)
Other comprehensive income (loss):
Foreign currency translation adjustments	29,988	(14,071)	81,313	(5,077)
Comprehensive loss	(1,511,365)	(661,005)	(4,261,126)	(1,554,903)
Less:
Net income attributable to non-controlling interests	0	(58,314)	(5,177)	(117,262)
Other comprehensive (income) loss attributable to non-controlling interests	0	(24,307)	32,967	(31,126)
Comprehensive (income) loss attributable to non-controlling interests	0	(82,621)	27,790	(148,388)
Comprehensive loss attributable to Eyegate Pharmaceuticals, Inc. stockholders	$ (1,511,365)	$ (743,626)	$ (4,233,336)	$ (1,703,291)

CONSOLIDATED STATEMENTS CONVERT

CONSOLIDATED STATEMENTS CONVERTIBLE PREFERRED STOCK NON-CONTROLLING INTERESTS AND STOCKHOLDERS' EQUITY (DEFICIT) - 6 months ended Jun. 30, 2015 - USD ($)	Total	Noncontrolling Interest [Member]	Convertible Preferred Stock and Non-Controlling Interests [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Stockholders' Notes Receivable [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Retained Earnings [Member]	Series A Convertible Preferred Stock [Member]	Series B Convertible Preferred Stock [Member]	Series C Convertible Preferred Stock [Member]	Series D Convertible Preferred Stock [Member]
Balance at Dec. 31, 2014	$ (46,806,801)	$ 6,780,588	$ 43,189,254	$ 2,018	$ 10,055,613	$ (58,824)	$ 56,544	$ (56,862,152)	$ 254,525	$ 6,926,180	$ 5,745,127	$ 23,482,834
Balance (in shares) at Dec. 31, 2014				201,787					2,483,692	8,073,508	3,351,156	19,557,392
Stock-based compensation	590,943		0		590,943
Issuance of common stock upon IPO	4,099,500		0	$ 6,833	4,092,667
Issuance of common stock upon IPO (in shares)				683,250
Expenses related to initial public offering	(1,373,858)		0		(1,373,858)
Conversion of preferred stock to common stock at $6.00 per share ($0.01 par value), net of deemed dividend of $8,222,008	36,408,666		(36,408,666)	$ 45,678	36,362,988				$ (254,525)	$ (6,926,180)	$ (5,745,127)	$ (23,482,834)
Conversion of preferred stock to common stock at $6.00 per share ($0.01 par value), net of deemed dividend of $8,222,008 (in shares)				4,567,782					(2,483,692)	(8,073,508)	(3,351,156)	(19,557,392)
Conversion of promissory notes to common stock at $4.20 per share	3,532,694		0	$ 8,660	3,524,034
Conversion of promissory notes to common stock at $4.20 per share (in shares)				866,056
Beneficial conversion feature on conversion of Notes upon the IPO	1,663,873		0		1,663,873
Exercise of common stock options	$ 14,948		0	$ 231	14,717
Exercise of common stock options (in shares)	23,075			23,075
Exercise of common warrants upon initial public offering			0	$ 97	(97)
Exercise of common warrants upon initial public offering (in shares)				9,748
Conversion of non-controlling interest to common stock	$ 6,818,732	(6,818,732)	(6,818,732)		6,818,732
Reclassification of previously issued warrant liability to stockholders' equity	79,930		0		79,930
Issuance of restricted stock	184,352			$ 1,254	183,098
Issuance of restricted stock (in shares)				125,412
Adjustment for fractional shares				(17)
Translation adjustment	48,346	32,967	32,967				48,346
Net income attributable to non-controlling interest	(12,569,624)	5,177	5,177					(4,347,616)
Balance at Jun. 30, 2015	$ 913,709	$ 0	$ 0	$ 64,771	$ 62,012,640	$ (58,824)	$ 104,890	$ (61,209,768)	$ 0	$ 0	$ 0	$ 0
Balance (in shares) at Jun. 30, 2015				6,477,093					0	0	0	0

CONSOLIDATED STATEMENTS CONVER6

CONSOLIDATED STATEMENTS CONVERTIBLE PREFERRED STOCK NON-CONTROLLING INTERESTS AND STOCKHOLDERS' EQUITY (DEFICIT) (Parenthetical) - USD ($)	6 Months Ended
	Jun. 30, 2015
Common Stock, Par or Stated Value Per Share	$ 0.01
Conversion of Stock Conversion Price Per Share	6
Debt Instrument, Convertible, Conversion Price	$ 4.20
Preferred Stock Dividends and Other Adjustments	$ 8,222,008

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Operating activities
Net loss	$ (4,342,439)	$ (1,549,826)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	684	943
Non-cash interest expense charge on beneficial conversion feature on notes	1,663,873	0
Non-cash interest expense on accounting of the debt discount	244,111	14,400
Fair value adjustment on common stock warrants	(223,172)	5,000
Stock-based compensation	775,295	24,089
Loss on cancellation of shareholders’ note receivable and related accrued interest receivable	0	200,758
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	(107,206)	(371)
Refundable tax credit receivable	798	(33,315)
Other assets	327	(582)
Accounts payable	(228,337)	215,932
Accrued expenses	(524,986)	638,693
Net cash used in operating activities	(2,741,052)	(484,279)
Investing activities:
Restricted cash	(20,000)	0
Net cash used in investing activities	(20,000)	0
Financing activities
Proceeds from convertible notes payable	0	932,829
Exercise of common stock options	14,948	0
Proceeds from initial public offering	4,099,500	0
Offering costs	(293,381)	(540,834)
Payments grants payable	(32,628)	0
Net cash provided by financing activities	3,788,439	391,995
Effect of exchange rate changes on cash	79,577	(7,067)
Net increase (decrease) in cash	1,106,964	(99,351)
Cash, beginning of period	167,001	501,172
Cash, end of period	1,273,965	401,821
Supplemental disclosure of noncash investing and financing activities
Conversion of non-controlling interests to common stock	6,818,732	0
Conversion of preferred stock into common stock	36,408,666	0
Exercise of common warrants	97	0
Conversion of promissory notes and accrued interest into common stock	3,532,694	0
Deemed dividend on conversion of preferred stock	8,222,008
Application of deferred offering costs on IPO	1,148,994
Warrant liability reclassed to stockholders’ equity	$ 79,930
Warrants issued to related parties in conjunction with issuance of amended convertible notes		$ 1,147,000

Nature of Business

Nature of Business	6 Months Ended
	Jun. 30, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of Operations [Text Block]	EyeGate Pharmaceuticals, Inc. (“EyeGate” or the “Company”), a Delaware corporation, began operations in December 2004 and is a clinical-stage specialty pharmaceutical company that is focused on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye. EyeGate’s first product in clinical trials incorporates a reformulated topically active corticosteroid, dexamethasone phosphate, that is delivered into the ocular tissues though our proprietary innovative drug delivery system, the EyeGate® II Delivery System. On February 13, 2015, the Company completed an initial public offering (“the IPO”) for 683,250 6.00 4,100,000 102,487 4.20 preferred shares were converted at the ratio of 10.98 shares of the preferred stock to 1.00 share of common stock 6,477,093 0.01 Since its inception, EyeGate has devoted substantially all of its efforts to business planning, research and development, and raising capital. The accompanying condensed consolidated financial statements have been prepared assuming that EyeGate will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. At June 30, 2015, EyeGate has cash and cash equivalents of $ 1,273,965 61,209,768 On August 5, 2015, the Company closed an underwritten 1,176,470 1,176,470 8.50 10.62 8.8

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2015
Accounting Policies [Abstract]
Significant Accounting Policies [Text Block]	2. Summary of Significant Accounting Policies The accompanying condensed consolidated financial statements include the accounts of the Company and EyeGate Pharma, wholly-owned subsequent to the IPO, majority owned prior to the IPO subsidiary of EyeGate, collectively referred to as the Company. The interests in EyeGate Pharma not owned by the Company prior to the IPO are reported in the consolidated balance sheet as of December 31, 2014 as non-controlling interests, a component of temporary equity, and the interest in the earnings or loss of the subsidiary not attributable to the Company is reported as net income (loss) attributable to non-controlling interests in the condensed consolidated statements of operations and comprehensive loss. Non-controlling interests represents the cumulative portion of equity and operating results of subsidiaries not owned by the Company. The non-controlling interests were convertible into shares of the Company’s convertible preferred stock (see Note 7) which were classified as temporary equity from January 1, 2015 through the date of the IPO, and for the three and six months ended June 30, 2014 and December 31, 2014 on the condensed consolidated balance sheet, and accordingly, the non-controlling interests are also classified as temporary equity on the condensed consolidated balance sheet. All inter-company balances and transactions have been eliminated in consolidation. These consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”). The accompanying interim financial statements and related disclosures are unaudited, have been prepared on the same basis as the annual financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for a fair statement of the results of operations for the periods presented. The year-end balance sheet was derived from audited financial statements, but does not include all disclosures required by U.S. GAAP. The results of operations for any interim period are not necessarily indicative of the results to be expected for the full year or for any other future year or interim period. The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make significant estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosure of contingent assets and liabilities, at the date of the financial statements, and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions are required in providing for fair value of warrants, establishing useful lives of intangible property and equipment assets and conducting impairment reviews of long-lived assets. The Company bases its estimates on historical experience and various other assumptions that it believes to be reasonable under the circumstances. Although the Company regularly assesses these estimates, actual results could differ materially from these estimates. Changes in estimates are recorded in the period in which they become known. Operations of EyeGate Pharma are conducted in euros which represent its functional currency. Balance sheet accounts of such subsidiary were translated into U.S. dollars at the exchange rate in effect at the balance sheet date and income statement accounts were translated to the average rate of exchange prevailing during the period. Translation adjustments resulting from this process, were included in accumulated other comprehensive income (loss) on the consolidated balance sheet. The Company considers all highly liquid investments purchased with maturity of 90 days or less when acquired, that are not restricted as to withdrawal, to be the equivalent of cash for the purpose of balance sheet and statement of cash flows presentation. Cash equivalents, which were nominal in amount, consisted of money market accounts that are readily convertible to cash. As of June 30, 2015 and December 31, 2014, the Company has classified $ 20,000 0 Property and equipment is stated at cost less accumulated depreciation. Depreciation is provided for on a straight-line basis over the estimated useful life of 3 7 The Company evaluates potential impairment of long-lived assets and long-lived assets to be disposed of and considers whether long-lived assets held for use have been impaired whenever events or changes in circumstances indicate that the related carrying amount may not be recoverable. Management makes significant estimates and assumptions regarding future sales, cost trends, productivity and market maturity in order to test for impairment. Management reports those long-lived assets to be disposed of and assets held for sale at the lower of carrying amount or fair value less cost to sell. Based on current facts, estimates and assumptions, management believes that no assets are impaired at June 30, 2015. There is no assurance that management’s estimates and assumptions will not change in future periods. Research and development expenditures are expensed as incurred. Research and development expenses are comprised of costs incurred in performing research and development activities, including salaries, benefits, facilities, research-related overhead, sponsored research costs, contracted services, license fees, and other external costs. Because the Company believes that, under its current process for developing its product, viability of the product is essentially concurrent with the establishment of technological feasibility, no costs have been capitalized to date. The Company provides deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the Company’s financial statements or tax returns. Deferred tax assets and liabilities are determined based on differences between the financial statement carrying amounts and the tax bases of the assets and liabilities using the enacted tax rates in effect in the years in which the differences are expected to reverse. A valuation allowance against deferred tax assets is recorded if, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. The Company recognizes the impact of an uncertain tax position in the financial statements if that position is more likely than not of being sustained by the taxing authority. As of June 30, 2015, the Company had no unrecognized uncertain tax positions. EyeGate Pharma is entitled to receive refundable tax credits associated with its research and development expenses in France. These tax credits can be realized, upon request of the Company, in the form of a cash payment or credits against tax liabilities. The Company records the refundable tax credit as income in the year in which the research and development expenses are incurred. The Company is largely dependent on obtaining financing to generate sufficient cash to cover operating costs. Through 2011, EyeGate Pharma, periodically issued preferred shares in exchange for U.S. dollar proceeds. At December 31, 2014, these shares represent a 49.99 50.01 49.99 Financial instruments that potentially subject the Company to significant concentrations of credit risk consist principally of cash and cash equivalents. The Company invests cash in accredited financial institutions and cash equivalents in widely held money market funds. Consequently, such funds are subject to minimal credit risk. The Company has no significant off-balance-sheet risk such as foreign exchange contracts, option contracts, or other foreign hedging arrangements. Comprehensive income (loss) is defined as the change in stockholders’ equity during a period from transactions, and other events and circumstances from non-owner sources. The foreign currency translation adjustments (see above) are the Company’s only component of other comprehensive income (loss). Stock-based compensation represents the cost related to stock-based awards granted to employees and others. The Company measures stock-based compensation cost to employees at grant date, based on the estimated fair value of the award, and recognizes the cost as expense on a straight-line basis (net of estimated forfeitures) over the employee requisite service period. The Company estimates the fair value of stock options using a Black-Scholes valuation model. The Company recognizes compensation expense for non-employee stock option grants at the fair value of the goods or services received or the equity instruments issued, whichever is more reliably measurable. The Company recorded compensation expense for non-employee awards with graded vesting using the accelerated expense attribution method. The Company records deferred tax assets for awards that result in deductions on the Company’s income tax returns, based on the amount of compensation expenses recognized and the Company’s statutory tax rate in the jurisdiction in which it will receive a deduction. Differences between the deferred tax assets recognized for financial reporting purposes and the actual tax benefit realized on the Company’s income tax return are recorded in additional paid-in capital if the tax benefit exceeds the deferred tax asset, or in the consolidated statements of operations if the deferred tax asset exceeds the tax benefit and no additional paid-in capital exists from previous awards. Basic and diluted net loss per common share is based on the weighted average number of shares outstanding common stock. June 30, 2015 December 31, (unaudited) 2014 Series A convertible preferred stock - 625,895 Series B convertible preferred stock (including 525,004 shares from conversion of non-controlling interest) - 1,262,651 Series C convertible preferred stock (including 187,183 shares from conversion of non-controlling interest) - 537,233 Series D convertible preferred stock (including 358,146 shares from conversion of non-controlling interest) - 2,145,810 Common stock warrants 637,980 18,176 Employee stock options 1,156,090 752,372 Total common shares issuable 1,794,070 5,342,137 The above table does not include shares issuable upon warrants issued to note holders or upon conversion of promissory notes (See Note 6) as the number of shares issuable under the warrants was not yet determinable at the grant date. The carrying amounts of receivables and payables approximate their fair values due to the short-term nature of these financial instruments. As of June 30, 2015 and December 31, 2014, the fair value of the Company’s money market funds was $ 1,250,234 187 Fair value of financial and non-financial assets and liabilities is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. The three-tier hierarchy for inputs used in measuring fair value, which prioritizes the inputs used in the methodologies of measuring fair value for assets and liabilities, is as follows: Level 1 - Quoted prices in active markets for identical assets or liabilities Level 2 - Observable inputs other than quoted prices in active markets for identical assets and liabilities Level 3 - No observable pricing inputs in the market Level 1 Level 2 Level 3 Total As of December 31, 2014 Non-current liabilities: Warrant liability $ - $ - $ 303,102 $ 303,102 Beginning balance at December 31, 2014 $ 303,102 Settlement of warrant liability (79,930) Change in fair value (223,172) Ending balance at June 30, 2015 $ 0 On February 13, 2015, the warrant liability was settled upon the consummation of the IPO. Deferred public offering costs, which primarily consist of direct, incremental legal and accounting fees relating to the Company’s initial public offering, are capitalized within deferred issuance costs. The deferred issuance costs were offset against IPO proceeds upon the consummation of the offering in February 2015. The Company had incurred approximately $ 1,149,000 68,517 In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2014-09 Revenue from Contracts with Customers In August 2014, the FASB issued ASU No. 2014-15, “Presentation of Financial Statements - Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern” (“ASU 2014-15”). ASU 2014-15 is intended to define management’s responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern and to provide related footnote disclosures. Specifically, ASU 2014-15 provides a definition of the term substantial doubt and requires an assessment for a period of one year after the date that the financial statements are issued (or available to be issued). It also requires certain disclosures when substantial doubt is alleviated as a result of consideration of management’s plans and requires an express statement and other disclosures when substantial doubt is not alleviated. The new standard will be effective for reporting periods beginning after December 15, 2016, with early adoption permitted. Management is currently evaluating the impact of the adoption of ASU 2014-15 on our financial statements and disclosures.

Property and Equipment

Property and Equipment	6 Months Ended
	Jun. 30, 2015
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment Disclosure [Text Block]	3. Property and Equipment June 30, Estimated Useful Life 2015 December 31, (Years) (Unaudited) 2014 Laboratory equipment 7 $ 14,661 $ 14,661 Computer equipment 3 182,914 182,914 Computer software 3 46,038 46,038 Furniture, fixtures and office equipment 5 24,480 24,480 268,093 268,093 Less accumulated depreciation 267,520 266,836 $ 573 $ 1,257 Depreciation expense was $ 684 943

Accrued Expenses

Accrued Expenses	6 Months Ended
	Jun. 30, 2015
Accrued Liabilities [Abstract]
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	4. Accrued Expenses June 30, December Payroll and benefits $ 55,710 $ 168,269 Clinical trials 122,334 57,629 Consulting 18,500 8,917 Professional fees 108,454 534,984 Accrued interest - 143,264 Total accrued expenses $ 304,998 $ 913,063

Grants Payable

Grants Payable	6 Months Ended
	Jun. 30, 2015
Grants Payable [Abstract]
Grants Payable Disclosure [Text Block]	5. Grants Payable In February 2007, the Company was awarded a second non-interest bearing grant from OSEO/Anvar of France. The balance of the grant payable was $ 0 36,401

Debt

Debt	6 Months Ended
	Jun. 30, 2015
Debt Disclosure [Abstract]
Debt Disclosure [Text Block]	6. Debt On December 21, 2012, the Company issued unsecured promissory notes (the “2012 Notes”) to certain stockholders in the aggregate principal amount of $ 525,000 8 December 10, 2013 1,058,270 533,000 88 On July 20, 2013, the Company entered into a Convertible Promissory Note Purchase Agreement (“Note Purchase Agreement”), pursuant to which the Company could issue up to an aggregate principal amount of $ 1,500,000 July 29, 2014 8 In the event that the Company issued equity securities resulting in gross proceeds to the Company of at least $3 million prior to maturity, the Company was to pay the note holders the repayment principal and all accrued and unpaid interest, at such time. In the event that the Company consummated a sale of the Company, as defined, the Company was to, while the 2012 Notes remain outstanding and at the election of the holders of two-thirds of the aggregate principal outstanding either (i) pay the holders the repayment principal amount plus accrued interest or (ii) immediately prior to the closing, convert all outstanding principal and interest into the Company’s Series D convertible preferred stock at 87.5% of the Series D convertible preferred stock conversion price. On July 29, 2013, the Company issued 2013 Notes in an aggregate principal amount of $ 968,970 446,151 16,667 On June 6, 2014, the Company entered into a Convertible Promissory Note and Warrant Purchase Agreement (“Note and Warrant Purchase Agreement”), pursuant to which the Company could issue up to an aggregate principal amount of $ 2,000,000 June 6, 2015 12 In the event that the Company issues equity securities, resulting in gross proceeds to the Company of at least $5 million prior to maturity, all outstanding principal and accrued and unpaid interest under the 2014 Notes will automatically convert into the newly issued equity securities at 70% of the offering price, as applicable, in connection with the closing of the first sale of the equity securities of the Company. In the event that the Company consummates a sale of the Company, as defined, the Company shall, while the 2014 Notes remain outstanding and at the election of the holders of two-thirds of the aggregate principal outstanding shall immediately prior to the closing, convert all outstanding principal and interest into the Company’s Series D convertible preferred stock (or other Subsequent Qualified Financing Instruments) at 70.0 The Company and each holder of 2012 and 2013 Notes executed an amended and restated promissory note (“Amended and Restated Notes”) in the principal amount of the sum of all outstanding principal and accrued and unpaid interest as at June 6, 2014, which aggregated approximately $ 2.1 As part of the Amended and Restated Notes, the requirement to pay the above mentioned premium of $ 533,000 200,000 260,000 660,000 586,000 The restructuring of the 2013 Notes resulted in a recognition of an extinguishment of debt as the terms of the new debt and of the original instrument are substantially different. The Company recorded a loss of $ 668,000 668,000 1.5 On June 6, 2014, July 17, 2014 and December 19, 2014, the Company issued 2014 Notes in an aggregate principal amount of approximately $ 1,283,000 495,000 288,000 219,000 288,000 34,000 1,039,000 244,000 The Company evaluated the features of the Amended and Restated Notes, and the 2014 Notes, to ascertain if the embedded conversion feature was required to be bifurcated and accounted for as a derivative. The Company evaluated whether the embedded feature met the definition of a derivative and determined that the conversion option does not as it does not meet the “net settlement” requirement. The underlying shares of the Company are those of a private company and are not considered readily convertible to cash, and therefore bifurcation is not required. The Company next considered whether the discount upon conversion required recognition of a beneficial conversion feature. Since the debt is only convertible in the instance of specific transactions, it is considered contingently convertible, and any beneficial conversion would only be recognized upon the occurrence of one of the contingent events. The Company issued to each holder of a 2014 Note or the Amended and Restated Notes, a warrant exercisable for common stock of the Company if the Company consummates an initial public offering (“IPO”) on or prior to December 31, 2014 or Series D convertible preferred stock at the original issuance price of such equity issuance if the IPO is not consummated on or prior to December 31, 2014 or if the Company is sold in 2014 in an M&A transaction consummated prior to the closing of the IPO. Under such scenario the number of warrants exercisable into Series D convertible stock would be approximately 2.1 1.22 Since the warrants are convertible into Series D Preferred Stock, which is a redeemable security and presented as temporary equity, these warrants are classified as liabilities. The Company determined the fair value of the warrants issued on June 6, 2014 and July 17, 2014 was approximately $ 1,364,000 • The number of warrants to be issued and the strike price will be determined based upon future events, including potential sale, liquidation or IPO transactions as described above. The Company utilized a probability weighting of potential outcomes to estimate the number of warrants issuable, the type of underlying security, and the exercise price. • Volatility - 70 • • Dividends - 0 • Discount rate - 0.6 1.6 The Company determined the fair value of the warrants issued on December 19, 2014 was approximately $ 34,000 • The number of warrants to be issued and the strike price will be determined based upon future events, including potential sale, liquidation or IPO transactions as described above. The Company utilized a probability weighting of potential outcomes to estimate the number of warrants issuable, the type of underlying security, and the exercise price. • Volatility - 55 • Term - 0.25 years for an IPO scenario; 4.5 years for an M&A or liquidation scenario • Dividends - 0 • Discount rate - 0.6 1.74 The Company utilized a probability weighting of the calculated values of the warrant utilizing a Black Scholes methodology to compute the estimated fair value. The Company will record changes in the fair value of the warrants in the statement of operations at each reporting period. The change in the fair value of the warrants for the six months ended June 30, 2015 was a decrease of approximately $ 223,000 80,000

Preferred Stock

Preferred Stock	6 Months Ended
	Jun. 30, 2015
Equity [Abstract]
Preferred Stock [Text Block]	7. Preferred Stock At June 30, 2015 and December 31, 2014, the Company had 10,000,000 50,485,136 2,483,692 13,819,649 5,161,241 29,020,554 December 31, 2014 Series A convertible preferred stock 2,483,692 Series B convertible preferred stock 8,073,508 Series C convertible preferred stock 3,351,156 Series D convertible preferred stock 19,557,392 Total preferred shares 33,465,748 As of June 30, 2015, the Company had no outstanding shares of preferred stock. Conversion All series of preferred stock were classified as temporary equity as the preferred stock was redeemable at the option of the holder in the event of a change in control. On February 13, 2015, the Company completed its Initial Public offering (“IPO”) and issued 683,250 2.7 4,567,782 30 8,222,000 3,532,694 866,056 30 1,633,873 The Company issued 23,075 14,948 The Company also acquired the remaining non-controlling interest of its SAS subsidiary, which resulted in the reclassification of the non-controlling interest to the Company’s additional paid-in-capital at the IPO date. The warrant liability was extinguished as the terms of the warrants provided for were settled upon the IPO being completed. The warrant liability was computed through February 13, 2015 and the resulting change in fair value was recorded in the statement of operations and the warrant liability was reclassified to additional paid-in-capital.

Warrants

Warrants	6 Months Ended
	Jun. 30, 2015
Warrants [Abstract]
Warrants Disclosure [Text Block]	8. Warrants Weighted Weighted Average Average Number of Exercise Remaining Awards Price Term in Years Outstanding at December 31, 2014 21,964 $ 4.52 1.56 Issued 630,733 $ 6.08 6.30 Exercised (10,929) $ 0.65 Forfeited (3,788) $ 14.45 Outstanding at June 30, 2015 637,980 $ 6.07 4.78 Warrants Remaining Term Exercise Price 7,247 .25 $ 5.16 630,733 6.30 $ 6.08 All of the warrant agreements contain a provision providing for a cashless exercise whereby, the number of warrants to be issued will be reduced by the number shares which could be purchased from the proceeds of the exercise of the respective warrant. The remaining warrants expire from 2015 through 2025.

Non-controlling interests

Non-controlling interests	6 Months Ended
	Jun. 30, 2015
Noncontrolling Interest [Abstract]
Noncontrolling Interest Disclosure [Text Block]	9. Non-controlling interests Series B convertible preferred stock 525,004 Series C convertible preferred stock 187,183 Series D convertible preferred stock 358,146 1,070,333 The subsidiary shares were convertible to Series B, Series C or Series D preferred shares of the Company, respectively, or to common stock of the Company, at the option of the holder (voluntary exchange) or mandatorily upon the occurrence of a Mandatory Exchange Event, as defined in the Exchange Agreement and accordingly the non-controlling interests are classified as temporary equity. All shares held by the non-controlling interests were converted into preferred shares, then into shares of the Company’s common stock at the closing of the Company’s IPO.

Stockholders' Notes Receivable

Stockholders' Notes Receivable	6 Months Ended
	Jun. 30, 2015
Receivables [Abstract]
Loans, Notes, Trade and Other Receivables Disclosure [Text Block]	10. Stockholders’ Notes Receivable In 2005 and 2006, certain of the Company’s stockholders and officers issued various promissory notes totaling $ 195,000 0.93 October 1, 2016 As of June 30, 2015 and December 31, 2014, $ 58,824

Equity Incentive Plan

Equity Incentive Plan	6 Months Ended
	Jun. 30, 2015
Share Based Compensation Option And Incentive Plan [Abstract]
Shareholders' Equity and Share-based Payments [Text Block]	11. Equity Incentive Plan In 2005, the Company approved the 2005 Equity Incentive Plan (the “2005 Plan”). The 2005 Plan provides for the granting of options, restricted stock or other stock-based awards to employees, officers, directors, consultants and advisors. During 2010, the maximum number of common shares that may be issued pursuant to the 2005 Plan was increased to 891,222 The Company’s Board adopted the 2014 Equity Incentive Plan, or the (“2014 Plan”) and the Employee Stock Purchase Plan the (“ESPP”), and the Company’s stockholders approved the 2014 Plan and the ESPP Plan in February 2015. The maximum number of Common Shares that may be issued pursuant to the 2014 Plan and the ESPP is 728,597 70,567 Weighted- Average Weighted-Average Number of Options Exercise Price Contractual Life (In Years) Outstanding at beginning of year 752,372 $ 0.91 4.55 Granted 435,393 5.80 9.63 Exercised (23,075) $ 0.65 Expired (Forfeited) (8,600) $ 0.65 Outstanding at end of period 1,156,090 $ 2.69 4.84 Exercisable at end of period 841,031 $ 2.70 4.75 Vested and expected to vest at end of period 841,031 $ 2.70 4.75 No options were granted in 2014. In September 2014, the Company entered into two consulting arrangements that provided for 60,358 Six months Ended June 30, 2015 2014 Research and development $ 202,191 $ 8,949 General and administrative 573,104 15,140 $ 775,295 $ 24,089 As of June 30, 2015, there is approximately $ 832,000 3.38 1,537,000 123,000 At June 30, 2015 there were 445,771 125,412 vest 13 % on the issuance date and 29% on each of the following-June 30, 2015, September 30, 2015 and December 31, 2015

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2015
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Text Block]	12. Commitments and Contingencies Operating Leases The Company has a lease for the rental of office space for its corporate headquarters. The lease covers the rental of up to 2,390 The Company executed a lease agreement in January 2013 which expired in June 2013. The Company exercised its option to continue the lease on a month to month basis. The agreement is cancellable by either party with one month notice. License Agreements The Company is a licensee under two license agreements that grant the Company the exclusive right to commercialize the technology related to its proprietary drug delivery system. Both license agreements require the Company to pay royalties to the licensor based on revenues related to the licensed technology. One of the license agreements requires the Company to pay an annual license fee of $ 12,500 100,000 12 15,036 240,000 Future minimum payments under the license as of March 31, 2015 are $ 12,500 Contingencies The Company neglected to file its Reports of Foreign Bank and Financial Accounts (“FBAR”) for 2011 and 2012 as required by the Bank Secrecy Act. The Company’s failure to file an FBAR when required may result in civil penalties, criminal penalties or both. The Company could be subject to penalties up to the greater of $100,000 per year or 50%

Employee Benefit Plans

Employee Benefit Plans	6 Months Ended
	Jun. 30, 2015
Postemployment Benefits [Abstract]
Compensation and Employee Benefit Plans [Text Block]	13. Employee Benefit Plans The Company has an employee benefit plan for its United States-based employees under Section 401(k) of the Internal Revenue Code. The Plan allows all eligible employees to make contributions up to a specified percentage of their compensation. Under the Plan, the Company may, but is not obligated to, match a portion of the employee contribution up to a defined maximum. The Company made no matching contribution for the six months ended June 30, 2015 and 2014.

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2015
Subsequent Events [Abstract]
Subsequent Events [Text Block]	14. Subsequent Events On July 9, 2015, the Company entered into an exclusive, worldwide licensing agreement with a subsidiary of Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) ("Valeant") through which EyeGate has granted Valeant exclusive, worldwide commercial and manufacturing rights to its EyeGate® II Delivery System and EGP-437 combination product ("Product") in the field of uveitis, as well as a right of last negotiation to license the Product for other indications. Under the agreement, Valeant paid us an upfront payment of $ 1.0 32.5 On August 5, 2015, the Company completed a public offering for 1,176,470 1,176,470 8.8 8.50 per share of common stock and warrant, 10.62 176,470 8.50 176,470 0.01

Summary of Significant Accoun22

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2015
Accounting Policies [Abstract]
Basis of Presentation and Principles of Consolidation [Policy Text Block]	Basis of Presentation and Principles of Consolidation The accompanying condensed consolidated financial statements include the accounts of the Company and EyeGate Pharma, wholly-owned subsequent to the IPO, majority owned prior to the IPO subsidiary of EyeGate, collectively referred to as the Company. The interests in EyeGate Pharma not owned by the Company prior to the IPO are reported in the consolidated balance sheet as of December 31, 2014 as non-controlling interests, a component of temporary equity, and the interest in the earnings or loss of the subsidiary not attributable to the Company is reported as net income (loss) attributable to non-controlling interests in the condensed consolidated statements of operations and comprehensive loss. Non-controlling interests represents the cumulative portion of equity and operating results of subsidiaries not owned by the Company. The non-controlling interests were convertible into shares of the Company’s convertible preferred stock (see Note 7) which were classified as temporary equity from January 1, 2015 through the date of the IPO, and for the three and six months ended June 30, 2014 and December 31, 2014 on the condensed consolidated balance sheet, and accordingly, the non-controlling interests are also classified as temporary equity on the condensed consolidated balance sheet. All inter-company balances and transactions have been eliminated in consolidation. These consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”).
Unaudited Interim Financial Information [Policy Text Block]	Unaudited Interim Financial Information The accompanying interim financial statements and related disclosures are unaudited, have been prepared on the same basis as the annual financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for a fair statement of the results of operations for the periods presented. The year-end balance sheet was derived from audited financial statements, but does not include all disclosures required by U.S. GAAP. The results of operations for any interim period are not necessarily indicative of the results to be expected for the full year or for any other future year or interim period.
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make significant estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosure of contingent assets and liabilities, at the date of the financial statements, and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions are required in providing for fair value of warrants, establishing useful lives of intangible property and equipment assets and conducting impairment reviews of long-lived assets. The Company bases its estimates on historical experience and various other assumptions that it believes to be reasonable under the circumstances. Although the Company regularly assesses these estimates, actual results could differ materially from these estimates. Changes in estimates are recorded in the period in which they become known.
Foreign Currency Transactions and Translations Policy [Policy Text Block]	Foreign Currency Translation Operations of EyeGate Pharma are conducted in euros which represent its functional currency. Balance sheet accounts of such subsidiary were translated into U.S. dollars at the exchange rate in effect at the balance sheet date and income statement accounts were translated to the average rate of exchange prevailing during the period. Translation adjustments resulting from this process, were included in accumulated other comprehensive income (loss) on the consolidated balance sheet.
Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and Cash Equivalents and Restricted Cash The Company considers all highly liquid investments purchased with maturity of 90 days or less when acquired, that are not restricted as to withdrawal, to be the equivalent of cash for the purpose of balance sheet and statement of cash flows presentation. Cash equivalents, which were nominal in amount, consisted of money market accounts that are readily convertible to cash. As of June 30, 2015 and December 31, 2014, the Company has classified $ 20,000 0
Property, Plant and Equipment, Policy [Policy Text Block]	Property and Equipment Property and equipment is stated at cost less accumulated depreciation. Depreciation is provided for on a straight-line basis over the estimated useful life of 3 7
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]	Impairment of Long-Lived Assets The Company evaluates potential impairment of long-lived assets and long-lived assets to be disposed of and considers whether long-lived assets held for use have been impaired whenever events or changes in circumstances indicate that the related carrying amount may not be recoverable. Management makes significant estimates and assumptions regarding future sales, cost trends, productivity and market maturity in order to test for impairment. Management reports those long-lived assets to be disposed of and assets held for sale at the lower of carrying amount or fair value less cost to sell. Based on current facts, estimates and assumptions, management believes that no assets are impaired at June 30, 2015. There is no assurance that management’s estimates and assumptions will not change in future periods.
Research and Development Expense, Policy [Policy Text Block]	Research and Development Expenses Research and development expenditures are expensed as incurred. Research and development expenses are comprised of costs incurred in performing research and development activities, including salaries, benefits, facilities, research-related overhead, sponsored research costs, contracted services, license fees, and other external costs. Because the Company believes that, under its current process for developing its product, viability of the product is essentially concurrent with the establishment of technological feasibility, no costs have been capitalized to date.
Income Tax, Policy [Policy Text Block]	Income Taxes The Company provides deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the Company’s financial statements or tax returns. Deferred tax assets and liabilities are determined based on differences between the financial statement carrying amounts and the tax bases of the assets and liabilities using the enacted tax rates in effect in the years in which the differences are expected to reverse. A valuation allowance against deferred tax assets is recorded if, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. The Company recognizes the impact of an uncertain tax position in the financial statements if that position is more likely than not of being sustained by the taxing authority. As of June 30, 2015, the Company had no unrecognized uncertain tax positions.
Income Tax Uncertainties, Policy [Policy Text Block]	Refundable Tax Credits for Research and Development EyeGate Pharma is entitled to receive refundable tax credits associated with its research and development expenses in France. These tax credits can be realized, upon request of the Company, in the form of a cash payment or credits against tax liabilities. The Company records the refundable tax credit as income in the year in which the research and development expenses are incurred.
Consolidation, Subsidiary Stock Issuances, Policy [Policy Text Block]	Sale of Stock by the Subsidiary The Company is largely dependent on obtaining financing to generate sufficient cash to cover operating costs. Through 2011, EyeGate Pharma, periodically issued preferred shares in exchange for U.S. dollar proceeds. At December 31, 2014, these shares represent a 49.99 50.01 49.99
Concentration of Credit Risk and Off-Balance-Sheet Risk Policy [Policy Text Block]	Financial instruments that potentially subject the Company to significant concentrations of credit risk consist principally of cash and cash equivalents. The Company invests cash in accredited financial institutions and cash equivalents in widely held money market funds. Consequently, such funds are subject to minimal credit risk. The Company has no significant off-balance-sheet risk such as foreign exchange contracts, option contracts, or other foreign hedging arrangements.
Comprehensive Income, Policy [Policy Text Block]	Comprehensive Income (Loss) Comprehensive income (loss) is defined as the change in stockholders’ equity during a period from transactions, and other events and circumstances from non-owner sources. The foreign currency translation adjustments (see above) are the Company’s only component of other comprehensive income (loss).
Compensation Related Costs, Policy [Policy Text Block]	Stock-Based Compensation Stock-based compensation represents the cost related to stock-based awards granted to employees and others. The Company measures stock-based compensation cost to employees at grant date, based on the estimated fair value of the award, and recognizes the cost as expense on a straight-line basis (net of estimated forfeitures) over the employee requisite service period. The Company estimates the fair value of stock options using a Black-Scholes valuation model. The Company recognizes compensation expense for non-employee stock option grants at the fair value of the goods or services received or the equity instruments issued, whichever is more reliably measurable. The Company recorded compensation expense for non-employee awards with graded vesting using the accelerated expense attribution method. The Company records deferred tax assets for awards that result in deductions on the Company’s income tax returns, based on the amount of compensation expenses recognized and the Company’s statutory tax rate in the jurisdiction in which it will receive a deduction. Differences between the deferred tax assets recognized for financial reporting purposes and the actual tax benefit realized on the Company’s income tax return are recorded in additional paid-in capital if the tax benefit exceeds the deferred tax asset, or in the consolidated statements of operations if the deferred tax asset exceeds the tax benefit and no additional paid-in capital exists from previous awards.
Earnings Per Share, Policy [Policy Text Block]	Net Loss per Share Basic and diluted net loss per common share is based on the weighted average number of shares outstanding common stock. June 30, 2015 December 31, (unaudited) 2014 Series A convertible preferred stock - 625,895 Series B convertible preferred stock (including 525,004 shares from conversion of non-controlling interest) - 1,262,651 Series C convertible preferred stock (including 187,183 shares from conversion of non-controlling interest) - 537,233 Series D convertible preferred stock (including 358,146 shares from conversion of non-controlling interest) - 2,145,810 Common stock warrants 637,980 18,176 Employee stock options 1,156,090 752,372 Total common shares issuable 1,794,070 5,342,137 The above table does not include shares issuable upon warrants issued to note holders or upon conversion of promissory notes (See Note 6) as the number of shares issuable under the warrants was not yet determinable at the grant date.
Fair Value of Financial Instruments, Policy [Policy Text Block]	Fair Value of Financial Instruments The carrying amounts of receivables and payables approximate their fair values due to the short-term nature of these financial instruments. As of June 30, 2015 and December 31, 2014, the fair value of the Company’s money market funds was $ 1,250,234 187 Fair value of financial and non-financial assets and liabilities is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. The three-tier hierarchy for inputs used in measuring fair value, which prioritizes the inputs used in the methodologies of measuring fair value for assets and liabilities, is as follows: Level 1 - Quoted prices in active markets for identical assets or liabilities Level 2 - Observable inputs other than quoted prices in active markets for identical assets and liabilities Level 3 - No observable pricing inputs in the market Level 1 Level 2 Level 3 Total As of December 31, 2014 Non-current liabilities: Warrant liability $ - $ - $ 303,102 $ 303,102 Beginning balance at December 31, 2014 $ 303,102 Settlement of warrant liability (79,930) Change in fair value (223,172) Ending balance at June 30, 2015 $ 0 On February 13, 2015, the warrant liability was settled upon the consummation of the IPO.
Deferred issuance costs Policy [Policy Text Block]	Deferred issuance costs Deferred public offering costs, which primarily consist of direct, incremental legal and accounting fees relating to the Company’s initial public offering, are capitalized within deferred issuance costs. The deferred issuance costs were offset against IPO proceeds upon the consummation of the offering in February 2015. The Company had incurred approximately $ 1,149,000 68,517
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2014-09 Revenue from Contracts with Customers In August 2014, the FASB issued ASU No. 2014-15, “Presentation of Financial Statements - Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern” (“ASU 2014-15”). ASU 2014-15 is intended to define management’s responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern and to provide related footnote disclosures. Specifically, ASU 2014-15 provides a definition of the term substantial doubt and requires an assessment for a period of one year after the date that the financial statements are issued (or available to be issued). It also requires certain disclosures when substantial doubt is alleviated as a result of consideration of management’s plans and requires an express statement and other disclosures when substantial doubt is not alleviated. The new standard will be effective for reporting periods beginning after December 15, 2016, with early adoption permitted. Management is currently evaluating the impact of the adoption of ASU 2014-15 on our financial statements and disclosures.

Summary of Significant Accoun23

Summary of Significant Accounting Policies (Tables)	6 Months Ended
	Jun. 30, 2015
Accounting Policies [Abstract]
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	In computing diluted loss per share, no effect has been given to the common shares issuable upon conversion or exercise of the following dilutive securities as the Company’s net loss would make the effect anti-dilutive. June 30, 2015 December 31, (unaudited) 2014 Series A convertible preferred stock - 625,895 Series B convertible preferred stock (including 525,004 shares from conversion of non-controlling interest) - 1,262,651 Series C convertible preferred stock (including 187,183 shares from conversion of non-controlling interest) - 537,233 Series D convertible preferred stock (including 358,146 shares from conversion of non-controlling interest) - 2,145,810 Common stock warrants 637,980 18,176 Employee stock options 1,156,090 752,372 Total common shares issuable 1,794,070 5,342,137
Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]	The following table represents the fair value of the warrant liability measured at fair value on a recurring basis: Level 1 Level 2 Level 3 Total As of December 31, 2014 Non-current liabilities: Warrant liability $ - $ - $ 303,102 $ 303,102
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	The following are the changes in the level 3 warrant liability for the six months ended June 30, 2015: Beginning balance at December 31, 2014 $ 303,102 Settlement of warrant liability (79,930) Change in fair value (223,172) Ending balance at June 30, 2015 $ 0

Property and Equipment (Tables)

Property and Equipment (Tables)	6 Months Ended
	Jun. 30, 2015
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment [Table Text Block]	Property and equipment at June 30, 2015 and December 31, 2014 consists of the following: June 30, Estimated Useful Life 2015 December 31, (Years) (Unaudited) 2014 Laboratory equipment 7 $ 14,661 $ 14,661 Computer equipment 3 182,914 182,914 Computer software 3 46,038 46,038 Furniture, fixtures and office equipment 5 24,480 24,480 268,093 268,093 Less accumulated depreciation 267,520 266,836 $ 573 $ 1,257

Accrued Expenses (Tables)

Accrued Expenses (Tables)	6 Months Ended
	Jun. 30, 2015
Accrued Liabilities [Abstract]
Schedule of Accrued Liabilities [Table Text Block]	Accrued expenses consist of the following: June 30, December Payroll and benefits $ 55,710 $ 168,269 Clinical trials 122,334 57,629 Consulting 18,500 8,917 Professional fees 108,454 534,984 Accrued interest - 143,264 Total accrued expenses $ 304,998 $ 913,063

Preferred Stock (Tables)

Preferred Stock (Tables)	6 Months Ended
	Jun. 30, 2015
Equity [Abstract]
Schedule of Preferred Stock Disclosure [Table Text Block]	As of December 31, 2014, the number of convertible preferred shares outstanding is as follows: December 31, 2014 Series A convertible preferred stock 2,483,692 Series B convertible preferred stock 8,073,508 Series C convertible preferred stock 3,351,156 Series D convertible preferred stock 19,557,392 Total preferred shares 33,465,748

Warrants (Tables)

Warrants (Tables)	6 Months Ended
	Jun. 30, 2015
Warrants [Abstract]
Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]	At June 30, 2015, the following warrants were outstanding: Weighted Weighted Average Average Number of Exercise Remaining Awards Price Term in Years Outstanding at December 31, 2014 21,964 $ 4.52 1.56 Issued 630,733 $ 6.08 6.30 Exercised (10,929) $ 0.65 Forfeited (3,788) $ 14.45 Outstanding at June 30, 2015 637,980 $ 6.07 4.78 Warrants Remaining Term Exercise Price 7,247 .25 $ 5.16 630,733 6.30 $ 6.08

Non-controlling interests (Tabl

Non-controlling interests (Tables)	6 Months Ended
	Jun. 30, 2015
Noncontrolling Interest [Abstract]
Schedule of Conversions of Stock [Table Text Block]	Shares issuable upon the conversion of non-controlling interests as of December 31, 2014 are as follows: Series B convertible preferred stock 525,004 Series C convertible preferred stock 187,183 Series D convertible preferred stock 358,146 1,070,333

Equity Incentive Plan (Tables)

Equity Incentive Plan (Tables)	6 Months Ended
	Jun. 30, 2015
Share Based Compensation Option And Incentive Plan [Abstract]
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	The following is a summary of stock option activity for the six months ended June 30, 2015: Weighted- Average Weighted-Average Number of Options Exercise Price Contractual Life (In Years) Outstanding at beginning of year 752,372 $ 0.91 4.55 Granted 435,393 5.80 9.63 Exercised (23,075) $ 0.65 Expired (Forfeited) (8,600) $ 0.65 Outstanding at end of period 1,156,090 $ 2.69 4.84 Exercisable at end of period 841,031 $ 2.70 4.75 Vested and expected to vest at end of period 841,031 $ 2.70 4.75
Employee and Non Employee Service Share Based Compensation Allocation off Recognized Period Costs [Table Text Block]	The total stock-based compensation expense for employees and non-employees is included in the accompanying consolidated statements of operations and as follows: Six months Ended June 30, 2015 2014 Research and development $ 202,191 $ 8,949 General and administrative 573,104 15,140 $ 775,295 $ 24,089

Nature of Business (Details Tex

Nature of Business (Details Textual) - USD ($)	Feb. 13, 2015	Aug. 05, 2015	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2014	Dec. 31, 2013
Subsidiary, Sale of Stock [Line Items]
Proceeds from Issuance Initial Public Offering			$ 4,099,500	$ 0
Debt Instrument, Convertible, Conversion Price	$ 4.20		$ 4.20
Common Stock, Shares, Outstanding			6,477,093
Common Stock, Par or Stated Value Per Share			$ 0.01		$ 0.01
Cash and Cash Equivalents, at Carrying Value			$ 1,273,965	$ 401,821	$ 167,001	$ 501,172
Retained Earnings (Accumulated Deficit)			$ (61,209,768)		$ (56,862,152)
Conversion of Stock, Description	preferred shares were converted at the ratio of 10.98 shares of the preferred stock to 1.00 share of common stock
IPO [Member]
Subsidiary, Sale of Stock [Line Items]
Sale of Stock, Number of Shares Issued in Transaction	683,250
Sale of Stock, Price Per Share	$ 6
Proceeds from Issuance Initial Public Offering	$ 4,100,000
Stock Issued During Period, Shares, New Issues	683,250
IPO [Member] | Subsequent Event [Member]
Subsidiary, Sale of Stock [Line Items]
Stock Issued During Period, Shares, New Issues		1,176,470
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		1,176,470
Shares Issued, Price Per Share		$ 8.50
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 10.62
Over-Allotment Option [Member]
Subsidiary, Sale of Stock [Line Items]
Sale of Stock, Number of Shares Issued in Transaction	102,487
Over-Allotment Option [Member] | Subsequent Event [Member]
Subsidiary, Sale of Stock [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		176,470
Proceeds from Issuance of Common Stock		$ 8,800,000

Summary of Significant Accoun31

Summary of Significant Accounting Policies (Details) - shares	6 Months Ended	12 Months Ended
	Jun. 30, 2015	Dec. 31, 2014
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	1,794,070	5,342,137
Employee Stock Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	1,156,090	752,372
Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	637,980	18,176
Series A Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	0	625,895
Series B Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	0	1,262,651
Series C Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	0	537,233
Series D Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	0	2,145,810

Summary of Significant Accoun32

Summary of Significant Accounting Policies (Details 1) - USD ($)	Jun. 30, 2015	Dec. 31, 2014
Non-current liabilities:
Warrant liability	$ 0	$ 303,102
Fair Value, Inputs, Level 1 [Member]
Non-current liabilities:
Warrant liability		0
Fair Value, Inputs, Level 2 [Member]
Non-current liabilities:
Warrant liability		0
Fair Value, Inputs, Level 3 [Member]
Non-current liabilities:
Warrant liability		$ 303,102

Summary of Significant Accoun33

Summary of Significant Accounting Policies (Details 2)	6 Months Ended
	Jun. 30, 2015USD ($)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Beginning balance at December 31, 2014	$ 303,102
Settlement of warrant liability	(79,930)
Change in fair value	(223,172)
Ending balance at June 30, 2015	$ 0

Summary of Significant Accoun34

Summary of Significant Accounting Policies (Details Textual) - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2015	Dec. 31, 2014	Feb. 13, 2015
Restricted Cash and Cash Equivalents, Noncurrent	$ 20,000	$ 0
Noncontrolling Interest, Ownership Percentage by Parent		49.99%	49.99%
Money Market Funds Fair Value	1,250,234	$ 187
Payments of Stock Issuance Costs	$ 68,517	$ 1,149,000
Equity Method Investment, Ownership Percentage		50.01%
Minimum [Member]
Property, Plant and Equipment, Useful Life	3 years
Maximum [Member]
Property, Plant and Equipment, Useful Life	7 years

Property and Equipment (Details

Property and Equipment (Details) - USD ($)	6 Months Ended
	Jun. 30, 2015	Dec. 31, 2014
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	$ 268,093	$ 268,093
Less accumulated depreciation	267,520	266,836
Property, Plant and Equipment, Net	573	1,257
Computer Software, Intangible Asset [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	$ 46,038	46,038
Property, Plant and Equipment, Useful Life	3 years
Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	$ 14,661	14,661
Property, Plant and Equipment, Useful Life	7 years
Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	$ 182,914	182,914
Property, Plant and Equipment, Useful Life	3 years
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	$ 24,480	$ 24,480
Property, Plant and Equipment, Useful Life	5 years

Property and Equipment (Detai36

Property and Equipment (Details Textual) - USD ($)	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Property, Plant and Equipment [Line Items]
Depreciation	$ 684	$ 943

Accrued Expenses (Details)

Accrued Expenses (Details) - USD ($)	Jun. 30, 2015	Dec. 31, 2014
Accrued Expenses [Line Items]
Total accrued expenses	$ 304,998	$ 913,063
Accrued Liabilities [Member]
Accrued Expenses [Line Items]
Payroll and benefits	55,710	168,269
Clinical trials	122,334	57,629
Consulting	18,500	8,917
Professional fees	108,454	534,984
Accrued interest	0	143,264
Total accrued expenses	$ 304,998	$ 913,063

Grants Payable (Details Textual

Grants Payable (Details Textual) - USD ($)	Jun. 30, 2015	Dec. 31, 2014
Grants Payable Current	$ 0	$ 36,401

Debt (Details Textual)

Debt (Details Textual) - USD ($) $ / shares in Units, shares in Millions	Feb. 13, 2015	Jun. 06, 2014	Dec. 19, 2014	Jul. 17, 2014	Apr. 15, 2014	Feb. 28, 2014	Jul. 29, 2013	Jul. 20, 2013	Dec. 21, 2012	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2014
Short-term Debt [Line Items]
Warrants and Rights Outstanding										$ 0		$ 0		$ 303,102
Long-term Debt, Gross														3,376,573
Fair Value Adjustment of Warrants										$ 0	$ 5,000	(223,172)	$ 5,000
Debt Instrument, Unamortized Discount	$ 244,000
2012 Notes Member
Short-term Debt [Line Items]
Debt Instrument, Face Amount									$ 525,000					586,000
Debt Instrument, Interest Rate, Stated Percentage									8.00%
Amortization of Debt Discount (Premium)									$ 533,000			$ 533,000
Debt Instrument, Interest Rate, Effective Percentage									88.00%
Debt Instrument, Maturity Amount									$ 1,058,270
Debt Instrument, Maturity Date									Dec. 10, 2013
Gains (Losses) on Restructuring of Debt														200,000
Warrants and Rights Outstanding														260,000
Long-term Debt, Gross														660,000
2013 Notes Member
Short-term Debt [Line Items]
Debt Instrument, Face Amount								$ 1,500,000
Debt Instrument, Interest Rate, Stated Percentage								8.00%
Debt Instrument, Maturity Date								Jul. 29, 2014
Debt Instrument, Payment Terms								In the event that the Company issued equity securities resulting in gross proceeds to the Company of at least $3 million prior to maturity, the Company was to pay the note holders the repayment principal and all accrued and unpaid interest, at such time. In the event that the Company consummated a sale of the Company, as defined, the Company was to, while the 2012 Notes remain outstanding and at the election of the holders of two-thirds of the aggregate principal outstanding either (i) pay the holders the repayment principal amount plus accrued interest or (ii) immediately prior to the closing, convert all outstanding principal and interest into the Companys Series D convertible preferred stock at 87.5% of the Series D convertible preferred stock conversion price.
Proceeds from Notes Payable					$ 16,667	$ 446,151	$ 968,970
Gains (Losses) on Restructuring of Debt														668,000
Warrants and Rights Outstanding														668,000
Long-term Debt, Gross														1,500,000
2014 Notes Member
Short-term Debt [Line Items]
Debt Instrument, Face Amount		$ 2,000,000
Debt Instrument, Interest Rate, Stated Percentage		12.00%
Amortization of Debt Discount (Premium)			$ 34,000	$ 219,000
Debt Instrument, Maturity Date		Jun. 6, 2015
Debt Instrument, Payment Terms		In the event that the Company issues equity securities, resulting in gross proceeds to the Company of at least $5 million prior to maturity, all outstanding principal and accrued and unpaid interest under the 2014 Notes will automatically convert into the newly issued equity securities at 70% of the offering price, as applicable, in connection with the closing of the first sale of the equity securities of the Company. In the event that the Company consummates a sale of the Company, as defined, the Company shall, while the 2014 Notes remain outstanding and at the election of the holders of two-thirds of the aggregate principal outstanding shall immediately prior to the closing, convert all outstanding principal and interest into the Companys Series D convertible preferred stock (or other Subsequent Qualified Financing Instruments) at 70.0% of the Series D convertible preferred stock original issuance price.
Proceeds from Notes Payable		$ 495,000	288,000											1,283,000
Warrants and Rights Outstanding		1,364,000	34,000	$ 1,364,000
Long-term Debt, Gross														$ 1,039,000
Fair Value Assumptions, Expected Term, Simplified Method												0.25 years for an IPO scenario; 4.5 years for an M&A or liquidation scenario		Term-0.5 years for an IPO scenario; 5 years for an M&A or liquidation scenario
Fair Value Assumptions, Expected Volatility Rate												55.00%		70.00%
Fair Value Assumptions, Expected Dividend Rate												0.00%		0.00%
Class of Warrant or Right, Number of Securities Called by Warrants or Rights														2.1
Class of Warrant or Right, Exercise Price of Warrants or Rights														$ 1.22
Fair Value Adjustment of Warrants												$ 223,000
Adjustments to Additional Paid in Capital, Warrant Issued	$ 80,000
2014 Notes Member | Minimum [Member]
Short-term Debt [Line Items]
Fair Value Inputs, Discount Rate												0.60%		0.60%
2014 Notes Member | Maximum [Member]
Short-term Debt [Line Items]
Fair Value Inputs, Discount Rate												1.74%		1.60%
Note and Warrant Purchase Agreement [Member]
Short-term Debt [Line Items]
Debt Instrument, Face Amount		$ 2,100,000
Proceeds from Notes Payable			$ 288,000

Preferred Stock (Details)

Preferred Stock (Details) - shares	Jun. 30, 2015	Dec. 31, 2014
Class of Stock [Line Items]
Preferred Stock, Shares Outstanding	0	0
Series A Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred Stock, Shares Outstanding		2,483,692
Series B Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred Stock, Shares Outstanding		8,073,508
Series C Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred Stock, Shares Outstanding		3,351,156
Series D Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred Stock, Shares Outstanding		19,557,392
Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred Stock, Shares Outstanding		33,465,748

Preferred Stock (Details Textua

Preferred Stock (Details Textual) - USD ($)	Feb. 13, 2015	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2014
Class of Stock [Line Items]
Preferred Stock, Shares Authorized		10,000,000		10,000,000
Preferred Stock, Conversion Basis		All outstanding shares of Series A, B, C and D preferred stock automatically converted to common stock immediately upon the closing of the Companys initial public offering in February 2015 at the conversion rates of 1:0.251, 1:0.091, 1:0.091, and 1:0.091, respectively.
Stock Issued During Period, Value, New Issues		$ 4,099,500
Convertible Preferred Stock Discount Rate At Initial Public Offering Price		30.00%
Dividends, Preferred Stock		$ 8,222,000
Conversion of Stock, Amount Issued		$ 3,532,694
Debt Conversion Original Debt Discount Rate At Initial Public Offering Price		30.00%
Debt Instrument, Convertible, Beneficial Conversion Feature		$ (1,663,873)	$ 0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period		23,075
Stock Issued During Period, Value, Stock Options Exercised		$ 14,948
IPO [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, New Issues	683,250
Stock Issued During Period, Value, New Issues	$ 2,700,000
Common Stock [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, New Issues		683,250
Stock Issued During Period, Value, New Issues		$ 6,833
Stock Issued During Period, Shares, Conversion of Convertible Securities		4,567,782
Conversion of Stock, Amount Issued		$ 8,660
Conversion of Stock, Shares Issued		866,056
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period		23,075
Stock Issued During Period, Value, Stock Options Exercised		$ 231
Common Stock [Member] | IPO [Member]
Class of Stock [Line Items]
Stock Issued During Period, Value, Stock Options Exercised		$ 14,948
Series A Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred Stock, Shares Authorized		2,483,692
Stock Issued During Period, Shares, Conversion of Convertible Securities		(2,483,692)
Series B Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred Stock, Shares Authorized		13,819,649
Stock Issued During Period, Shares, Conversion of Convertible Securities		(8,073,508)
Series C Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred Stock, Shares Authorized		5,161,241
Stock Issued During Period, Shares, Conversion of Convertible Securities		(3,351,156)
Series D Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred Stock, Shares Authorized		29,020,554
Stock Issued During Period, Shares, Conversion of Convertible Securities		(19,557,392)

Warrants (Details)

Warrants (Details) - Warrant [Member] - $ / shares	6 Months Ended	12 Months Ended
	Jun. 30, 2015	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number ofShares, Outstanding at December 31, 2014	21,964
Number ofShares, Issued	630,733
Number ofShares, Exercised	(10,929)
Number ofShares, Forfeited	(3,788)
Number ofShares, Outstanding at June 30, 2015	637,980	21,964
Weighted Average Exercise Price, Outstanding at December 31, 2014	$ 4.52
Weighted Average Exercise Price, Issued	6.08
Weighted Average Exercise Price, Exercised	0.65
Weighted Average Exercise Price, Forfeited	14.45
Weighted Average Exercise Price, Outstanding at June 30, 2015	$ 6.07	$ 4.52
Weighted Average Remaining Term in Years, Issued	6 years 3 months 18 days	1 year 6 months 22 days
Weighted Average Remaining Term in Years, Outstanding at June 30, 2015	4 years 9 months 11 days

Warrants (Details 1)

Warrants (Details 1) - Jun. 30, 2015 - $ / shares	Total
Exercise Price One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Outstanding Options	7,247
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Remaining Contractual Terms	3 months
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value	$ 5.16
Exercise Price Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Outstanding Options	630,733
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Remaining Contractual Terms	6 years 3 months 18 days
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value	$ 6.08

Non-controlling interests (Deta

Non-controlling interests (Details)	12 Months Ended
	Dec. 31, 2014shares
Conversion of Subsidiary Stock Shares Issuable	1,070,333
Series B Convertible Preferred Stock [Member]
Conversion of Subsidiary Stock Shares Issuable	525,004
Series C Convertible Preferred Stock [Member]
Conversion of Subsidiary Stock Shares Issuable	187,183
Series D Convertible Preferred Stock [Member]
Conversion of Subsidiary Stock Shares Issuable	358,146

Stockholders' Notes Receivable

Stockholders' Notes Receivable (Details Textual) - USD ($)	12 Months Ended	24 Months Ended
	Dec. 31, 2012	Dec. 31, 2006	Jun. 30, 2015	Dec. 31, 2014	Oct. 01, 2012
Debt Instrument [Line Items]
Receivable from Shareholders or Affiliates for Issuance of Capital Stock			$ 58,824	$ 58,824
Commercial Paper [Member]
Debt Instrument [Line Items]
Notes Issued		$ 195,000
Debt Instrument, Interest Rate, Effective Percentage					0.93%
Debt Instrument, Maturity Date	Oct. 1, 2016
Receivable from Shareholders or Affiliates for Issuance of Capital Stock			$ 58,824	$ 58,824

Equity Incentive Plan (Details)

Equity Incentive Plan (Details) - $ / shares	6 Months Ended	12 Months Ended
	Jun. 30, 2015	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options, Exercised	(23,075)
Equity Incentive Plan 2014 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options, Outstanding beginning of year	752,372
Number of Options, Granted	435,393
Number of Options, Exercised	(23,075)
Number of Options, Expired (Forfeited)	(8,600)
Number of Options, Outstanding at end of period	1,156,090	752,372
Number of Options, Exercisable at end of period	841,031
Number of Options, Vested and expected to vest at end of period	841,031
Weighted average exercise price, Outstanding at beginning of year	$ 0.91
Weighted average exercise price, Granted	5.8
Weighted average exercise price, Exercised	0.65
Weighted average exercise price, Expired	0.65
Weighted average exercise price, Outstanding at end of period	2.69	$ 0.91
Weighted average exercise price, Exercisable at end of period	2.70
Weighted average exercise price, Vested and expected to vest at end of period	$ 2.70
Weighted average contractual life (In Years) Outstanding	4 years 10 months 2 days	4 years 6 months 18 days
Weighted average contractual life (In Years) Granted	9 years 7 months 17 days
Weighted average remaining exercisable contractual life (In Years)	4 years 9 months
Weighted average remaining vested and expected to vest contractual life (In Years)	4 years 9 months

Equity Incentive Plan (Details

Equity Incentive Plan (Details 1) - USD ($)	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost	$ 775,295	$ 24,089
Research and Development Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost	202,191	8,949
General and Administrative Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost	$ 573,104	$ 15,140

Equity Incentive Plan (Detail48

Equity Incentive Plan (Details Textual) - USD ($)	1 Months Ended	6 Months Ended
	Feb. 28, 2015	Jun. 30, 2015	Jun. 30, 2014	May. 01, 2015	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized		$ 832,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition		3 years 4 months 17 days
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding And Exercisable Intrinsic Value		$ 1,537,000
Proceeds from Stock Options Exercised		$ 14,948	$ 0
Equity Incentive Plan 2005 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized					891,222
ESPP [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant		70,567
2005 And 2014 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant		445,771
2014 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant		728,597
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant				125,412
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights		vest 13 % on the issuance date and 29% on each of the following-June 30, 2015, September 30, 2015 and December 31, 2015
IPO [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock Issued During Period, Shares, Other	60,358

Commitments and Contingencies (

Commitments and Contingencies (Details Textual)	Jul. 07, 2014shares	Jan. 31, 2012USD ($)	Jun. 30, 2015USD ($)ft²	Dec. 31, 2014USD ($)
Commitments and Contingencies [Line Items]
Area of Land | ft²			2,390
License Expiration Period		12 years
Net Extinguished, Fair Value of Stock Consideration Received				$ 240,000
License Costs			$ 12,500
Payments for Royalties		$ 100,000
Operating Leases, Future Minimum Payments Due			$ 12,500
Description on Civil Penalties for Failure to File an FBAR			greater of $100,000 per year or 50%
Licensor [Member]
Commitments and Contingencies [Line Items]
Stock Issued During Period, Shares, Other | shares	15,036

Subsequent Events (Details Text

Subsequent Events (Details Textual) - USD ($) $ / shares in Units, $ in Millions	Feb. 13, 2015	Aug. 05, 2015	Jul. 31, 2015
Valeant Pharmaceuticals International Inc [Member] | Licensing Agreements [Member]
Subsequent Event [Line Items]
Payments to Acquire Intangible Assets			$ 1
Proceeds from Sale of Intangible Assets			$ 32.5
IPO [Member]
Subsequent Event [Line Items]
Stock Issued During Period, Shares, New Issues	683,250
Subsequent Event [Member] | Representative The Underwriters [Member]
Subsequent Event [Line Items]
Shares Issued, Price Per Share		$ 8.50
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		176,470
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 0.01
Subsequent Event [Member] | IPO [Member]
Subsequent Event [Line Items]
Stock Issued During Period, Shares, New Issues		1,176,470
Shares Issued, Price Per Share		$ 8.50
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		1,176,470
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 10.62
Subsequent Event [Member] | Over-Allotment Option [Member]
Subsequent Event [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		176,470
Proceeds from Issuance of Common Stock		$ 8.8